The IRA Promised Lower Drug Prices. Why Did It Cut Follow-On Cancer Research?
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Harry Bowen, Economics Research Partner at Vital Transformation, about their newly published study on the Inflation Reduction Act (IRA) and late-stage drug research, including additional uses of medicines after their first FDA approval.
They explain why separating small molecules from biologics and examining the mix of research across disease areas can reveal patterns hidden in aggregate results. The conversation also covers policy expectations, venture capital, global biopharma competition, and the economic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.